Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $9.66 Consensus Target Price from Analysts

Revance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) has been given a consensus recommendation of "Hold" by the nine ratings firms that are presently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $9.66.

A number of brokerages have issued reports on RVNC. Stifel Nicolaus cut their price target on shares of Revance Therapeutics from $24.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, August 9th. HC Wainwright reissued a "neutral" rating and set a $6.60 price objective on shares of Revance Therapeutics in a research report on Friday. Barclays reaffirmed an "equal weight" rating and set a $7.00 price objective (down from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th. StockNews.com began coverage on Revance Therapeutics in a research report on Sunday. They set a "hold" rating on the stock. Finally, Guggenheim restated a "neutral" rating on shares of Revance Therapeutics in a research report on Monday, August 12th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets lifted its holdings in shares of Revance Therapeutics by 342.1% in the first quarter. BNP Paribas Financial Markets now owns 211,695 shares of the biopharmaceutical company's stock valued at $1,042,000 after buying an additional 163,809 shares during the period. Swiss National Bank boosted its holdings in shares of Revance Therapeutics by 18.2% in the first quarter. Swiss National Bank now owns 194,650 shares of the biopharmaceutical company's stock worth $958,000 after buying an additional 30,000 shares during the period. NorthRock Partners LLC purchased a new position in shares of Revance Therapeutics in the first quarter worth approximately $151,000. Inspire Investing LLC raised its holdings in shares of Revance Therapeutics by 68.1% during the first quarter. Inspire Investing LLC now owns 73,160 shares of the biopharmaceutical company's stock valued at $360,000 after acquiring an additional 29,645 shares during the period. Finally, Blair William & Co. IL boosted its stake in Revance Therapeutics by 3.6% in the 1st quarter. Blair William & Co. IL now owns 329,267 shares of the biopharmaceutical company's stock worth $1,620,000 after purchasing an additional 11,318 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Revance Therapeutics Price Performance

NASDAQ:RVNC traded up $0.76 during trading hours on Tuesday, reaching $4.21. The company had a trading volume of 5,828,981 shares, compared to its average volume of 2,784,417. The business's 50 day moving average price is $5.60 and its 200-day moving average price is $4.43. Revance Therapeutics has a 1-year low of $2.30 and a 1-year high of $9.74. The firm has a market cap of $441.29 million, a PE ratio of -2.02 and a beta of 0.95.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The company had revenue of $59.88 million during the quarter, compared to analysts' expectations of $67.73 million. On average, analysts expect that Revance Therapeutics will post -1.53 earnings per share for the current fiscal year.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.